Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• Macaques immunized with uninfected human cells showed protection against simian immunodeficiency virus (SIV) propagated in human cells.
• Identifying specific antigens responsible for this protection is crucial for understanding antiviral immune responses.

Purpose of the Study:

• To determine which cellular antigens, when used for immunization, confer protection against SIV challenge.
• To investigate whether protection is mediated by antibodies against cellular proteins or cross-reactive epitopes.

Main Methods:

• Macaques were immunized with various components of human cells, including beta-2 microglobulin (beta 2M), HLA class I, HLA class II proteins, and mock virus.
• Animals were challenged with SIV propagated in human cells and subsequently with SIV propagated in macaque cells.
• Antibody titers and protection levels were assessed post-challenge.

Main Results:

• Immunization with beta 2M or HLA class I did not protect against SIV challenge.
• Immunization with HLA class II protein (HLA-DR) or mock virus conferred protection against SIV propagated in human cells.
• Protection was not observed when challenged with SIV propagated in macaque cells, indicating specificity to human class II proteins.

Conclusions:

• Protection against SIV infection is mediated by an immune response to human class II proteins, not cross-reactive epitopes with viral proteins.
• This study demonstrates that immunization with a purified cellular protein can induce protection against virus infection.
• The findings highlight the potential of targeting cellular proteins in vaccine strategies against viral pathogens.